RxDoctor Payments Data

Marie Hughes

Family Medicine · Saint Helena, CANPI 1508273095

Payments from drug & device makers

$1,694in general payments, 2019–2025

Across 105 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$522
  • Medtronic$225
  • AbbVie$224
  • Lilly USA, LLC$152
  • Intuitive Surgical$98
  • Organon$89
  • plus $384 from 11 others

What the payments were for

  • Food & beverage$1,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,694 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$360,717
Medicare patients
614
Services billed
5,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$99,655
EliquisApixaban85$74,773
JardianceEmpagliflozin59$56,509
ClozarilClozapine12$42,244
MounjaroTirzepatide26$31,446
CreonLipase/Protease/Amylase19$24,020
TrulicityDulaglutide15$23,283
Soliqua 100-33Insulin Glargine/Lixisenatide14$21,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,032
MyrbetriqMirabegron22$17,609
FarxigaDapagliflozin Propanediol17$15,286
XareltoRivaroxaban11$13,407
Levothyroxine Sodium361$4,220
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$3,773
Estradiol62$3,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$522$99,65583 claims
PfizerEliquis$84$74,77385 claims
Boehringer IngelheimJardiance$39$56,50959 claims
Lilly USA, LLCMounjaro, Trulicity$152$54,72941 claims
AbbVieCreon, Synthroid$224$25,44171 claims
GSKTrelegy Ellipta$36$19,03216 claims
Johnson & JohnsonXarelto$37$13,40711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Saint Helena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →